| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prostaglandin-producing suppressor cells in Hodgkin's disease.
|
N Engl J Med
|
1977
|
3.38
|
|
2
|
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
|
Cancer Treat Rep
|
1976
|
1.45
|
|
3
|
Paraplegia following intrathecal chemotherapy.
|
Cancer
|
1972
|
1.09
|
|
4
|
Peripheral blood T- and B-lymphocytes in patients with lymphoma and acute leukemia.
|
Clin Immunol Immunopathol
|
1973
|
1.02
|
|
5
|
Institutional performance in application of the FAB classification of acute leukemia. The Southwest Oncology Group experience.
|
Cancer
|
1985
|
0.96
|
|
6
|
Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy.
|
Blood
|
1989
|
0.91
|
|
7
|
Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.
|
Leukemia
|
1992
|
0.91
|
|
8
|
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
|
Cancer Treat Rep
|
1977
|
0.91
|
|
9
|
Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma.
|
Cancer Res
|
1984
|
0.90
|
|
10
|
Diabetes mellitus among the Navajo. I. Clinical features.
|
Arch Intern Med
|
1968
|
0.89
|
|
11
|
5-azacytidine in acute leukemia.
|
Cancer
|
1978
|
0.87
|
|
12
|
Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study.
|
Cancer
|
1981
|
0.85
|
|
13
|
Diabetes mellitus among the Navajo. II. Plasma glucose and insulin responses.
|
Arch Intern Med
|
1968
|
0.82
|
|
14
|
Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide.
|
Arch Intern Med
|
1974
|
0.82
|
|
15
|
Reproducibility of the French-American-British classification of acute leukemia: the Southwest Oncology Group Experience.
|
Am J Hematol
|
1985
|
0.78
|
|
16
|
Tamoxifen therapy and colorectal adenocarcinoma: a Southwest Oncology Group study.
|
Cancer Treat Rep
|
1985
|
0.77
|
|
17
|
Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study.
|
Am J Clin Oncol
|
1983
|
0.77
|
|
18
|
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
|
Cancer
|
1980
|
0.76
|
|
19
|
A useful high-dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas.
|
Cancer
|
1986
|
0.76
|
|
20
|
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
|
Cancer
|
1977
|
0.76
|
|
21
|
Suppressor leukocytes in anergic patients with solid tumors.
|
J Clin Lab Immunol
|
1980
|
0.75
|
|
22
|
Idiopathic hemochromatosis: serum ferritin concentrations during therapy by phlebotomy.
|
Clin Chem
|
1982
|
0.75
|
|
23
|
Icteric serum: a helpful diagnostic clue in comatose patients.
|
South Med J
|
1969
|
0.75
|
|
24
|
Extravasation of chemotherapeutic agents.
|
Clin Orthop Relat Res
|
1980
|
0.75
|
|
25
|
Adriamycin therapy in previously treated adult acute leukemia.
|
Cancer Treat Rep
|
1977
|
0.75
|
|
26
|
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
|
Urology
|
1978
|
0.75
|
|
27
|
An approach to anemia.
|
Rocky Mt Med J
|
1970
|
0.75
|
|
28
|
Medical ethics rounds. Development and organization.
|
Rocky Mt Med J
|
1980
|
0.75
|
|
29
|
Severe myxedema following inadvertent removal of an ectopic thyroid resembling a thyroglossal duct cyst.
|
J Lancet
|
1967
|
0.75
|
|
30
|
Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group Study.
|
Cancer Treat Rep
|
1982
|
0.75
|
|
31
|
Adjuvant chemotherapy of breast cancer.
|
Rocky Mt Med J
|
1976
|
0.75
|
|
32
|
Adriamycin combined with 10-day Ara-C, vincristine, and prednisone (10-day ADOAP) in the treatment of adult acute leukemia patients under fifty years of age. A Southwest Oncology Group Study.
|
Am J Clin Oncol
|
1982
|
0.75
|